| Biomarker ID | 1579 |
| PMID | 25274378 |
| Year | 2014 |
| Biomarker | (Intergenic) LILRB2–LILRA3 [SNP: rs103294] |
| Biomarker Basis | Mutation Based |
| Biomolecule | Mutation |
| Source | Blood |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | OR: 0.65 (95% CI: 0.45–0.95) |
| Effect on Pathways | NA |
| Experiment | Gleason Score ≤ 6 Vs Gleason Score ≥ 8 |
| Type of Biomarker | Prognostic |
| Cohort | 1827 men with Prostate cancer were selected for the study. 675 had Gleason Score ≤ 6 and 231 had GS ≥ 8. 921 had GS=7 |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.024 |
| Method Used | QIAamp DNA extraction Kit (QIAGEN) |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |